
Shashank Tripathi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2996039/publications.pdf Version: 2024-02-01



SHASHANK TRIDATHI

#	Article	IF	CITATIONS
1	Meta- and Orthogonal Integration of Influenza "OMICs―Data Defines a Role for UBR4 in Virus Budding. Cell Host and Microbe, 2015, 18, 723-735.	11.0	868
2	Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling. Cell Host and Microbe, 2016, 19, 882-890.	11.0	658
3	Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science, 2017, 356, 175-180.	12.6	453
4	Dengue virus NS2B protein targets cGAS for degradation and prevents mitochondrial DNA sensing during infection. Nature Microbiology, 2017, 2, 17037.	13.3	292
5	Comparative Flavivirus-Host Protein Interaction Mapping Reveals Mechanisms of Dengue and Zika Virus Pathogenesis. Cell, 2018, 175, 1931-1945.e18.	28.9	252
6	A novel Zika virus mouse model reveals strain specific differences in virus pathogenesis and host inflammatory immune responses. PLoS Pathogens, 2017, 13, e1006258.	4.7	200
7	An Immunocompetent Mouse Model of Zika Virus Infection. Cell Host and Microbe, 2018, 23, 672-685.e6.	11.0	192
8	Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection. Immunity, 2016, 44, 46-58.	14.3	110
9	The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon response. PLoS Pathogens, 2019, 15, e1007634.	4.7	67
10	Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection. Frontiers in Cellular and Infection Microbiology, 2020, 10, 580096.	3.9	66
11	Influenza virus repurposes the antiviral protein IFIT2 to promote translation of viral mRNAs. Nature Microbiology, 2020, 5, 1490-1503.	13.3	45
12	Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. ACS Infectious Diseases, 2021, 7, 2546-2564.	3.8	34
13	Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2. ELife, 2022, 11, .	6.0	28
14	Identification of COVID-19 prognostic markers and therapeutic targets through meta-analysis and validation of Omics data from nasopharyngeal samples. EBioMedicine, 2021, 70, 103525.	6.1	27
15	Systems-based analysis of RIG-I-dependent signalling identifies KHSRP as an inhibitor of RIG-I receptor activation. Nature Microbiology, 2017, 2, 17022.	13.3	25
16	Restriction factor compendium for influenza A virus reveals a mechanism for evasion of autophagy. Nature Microbiology, 2021, 6, 1319-1333.	13.3	23
17	Interplay between influenza A virus and host factors: targets for antiviral intervention. Archives of Virology, 2015, 160, 1877-1891.	2.1	21
18	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. Expert Review of Anti-Infective Therapy, 2022, 20, 1275-1298.	4.4	21

SHASHANK TRIPATHI

#	Article	IF	CITATIONS
19	Enhancement of the Proapoptotic Properties of Newcastle Disease Virus Promotes Tumor Remission in Syngeneic Murine Cancer Models. Molecular Cancer Therapeutics, 2015, 14, 1247-1258.	4.1	20
20	Moving from Empirical to Rational Vaccine Design in the â€~Omics' Era. Vaccines, 2019, 7, 89.	4.4	19
21	A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern. Frontiers in Immunology, 2021, 12, 765211.	4.8	16
22	Specific Mutations in the PB2 Protein of Influenza A Virus Compensate for the Lack of Efficient Interferon Antagonism of the NS1 Protein of Bat Influenza A-Like Viruses. Journal of Virology, 2018, 92,	3.4	11
23	Antiviral innate immunity through the lens of systems biology. Virus Research, 2016, 218, 10-17.	2.2	10
24	Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. Clinical Microbiology Reviews, 2022, 35, e0012321.	13.6	10
25	Live Visualization of Hemagglutinin Dynamics during Infection by Using a Novel Reporter Influenza A Virus. Viruses, 2020, 12, 687.	3.3	2
26	INNATE IMMUNE SUBVERSION STRATEGIES OF HUMAN FLAVIVIRUSES. Critical Reviews in Immunology, 2021, 41, 27-42.	0.5	1